Increasing access to biosimilar medicines.

HB 1725 requires health plans in Washington to streamline access to biosimilar medicines (safe, effective, lower-cost alternatives to brand-name biologics) by mandating clear exception processes for coverage denials. It directly affects patients, doctors, and health insurance companies by requiring health plans to: (1) post plain-language exception rules online, (2) approve exceptions meeting specific medical criteria (like drug ineffectiveness or adverse reactions), and (3) follow strict timelines (1-3 business days) for urgent/non-urgent requests. The bill eliminates barriers by ensuring health plans must cover biosimilars when clinical evidence supports them, with automatic approval if deadlines are missed. This aims to reduce prescription drug costs without altering drug approval standards.